Review Article

Genetic Polymorphism rs6505162 in MicroRNA-423 May Not Be Associated with Susceptibility of Breast Cancer: A Systematic Review and Meta-Analysis

Zhi Li, 1 Jin Wang, 2 Hui-bing Chen, 3 Xiao-Mei Guo, 1 Xiao-Ping Chen, 4 Meng Wang, 1 Li-Juan Dong 5, 1 and Min-Min Zhang 5

1 Department of Nursing, Zhongshan Hospital of Chinese Traditional Medicine, Zhongshan 528400, China
2 Department of Nephrology, Zhongshan Hospital of Chinese Traditional Medicine, Zhongshan 528400, China
3 Department of Anorectal, Zhongshan Hospital of Chinese Traditional Medicine, Zhongshan 528400, China
4 Department of Oncology, Zhongshan Hospital of Chinese Traditional Medicine, Zhongshan 528400, China
5 Department of Thyroid and Breast Surgery, Liuzhou People’s Hospital, Liuzhou 545005, China

Correspondence should be addressed to Li-Juan Dong; lizhidonglijuan@163.com and Min-Min Zhang; zhmmeva@126.com

Received 24 August 2021; Revised 8 October 2021; Accepted 13 October 2021; Published 26 November 2021

Academic Editor: Yuan Seng Wu

Copyright © 2021 Zhi Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. MicroRNA-423 (miR-423) rs6505162 polymorphism is found to be associated with breast cancer (BC) risk. However, the results were inconsistent. This study meta-analyzed the literature on possible association between rs6505162 polymorphism and BC risk. Methods. PubMed, Embase, Google Scholar, and the Chinese National Knowledge Infrastructure (CNKI) databases were systematically searched to identify relevant studies. Meta-analyses were performed to examine the association between rs6505162 polymorphism and BC. Results. None of the five genetic models suggested a significant association between rs6505162 polymorphism and BC risk: allelic model, OR 1.02, 95% CI 0.18–1.28, P = 0.85; recessive model, OR 0.99, 95% CI 0.72–1.38, P = 0.97; dominant model, OR 0.93, 95% CI 0.72–1.21, P = 0.60; homozygous model, OR 1.04, 95% CI 0.66–1.65, P = 0.87; and heterozygous model, OR 1.07, 95% CI 0.90–1.28, P = 0.45. Similar results were obtained in subgroup analyses of Asian, Chinese, and Caucasian patients. Conclusion. The available evidence suggests no significant association between rs6505162 polymorphism and BC risk. These conclusions should be verified in large, well-designed studies.

1. Introduction

Breast cancer (BC) continues to disrupt the lives of millions of women. For many years, BC has consistently ranked among the top cancers in the women, both in terms of incidence and mortality [1]. As we all know, age, menstrual status (early menarche age and delayed menopause), reproduction (late age at first birth), genetic predisposition (higher incidence among close family members and first degree relatives in the breast cancer patients), lifestyle (saturated fat diet, alcohol excessive intake, and obesity), and so on are generally considered to be the causes of BC [2]. However, most causes of BC are not yet clearly understood. Genetic factors have been reported to play an important role in BC development. For instance, mutation in BRCA1 and BRCA2 and low-penetrance common genetic variants were identified as breast cancer risk factors [3]. Recent research studies have shown that one miRNA can potentially affect the expression of many genes to various degrees, and it could participate in the control of numerous metabolic pathways, including cellular growth and differentiation, suggesting that single nucleotide polymorphisms located within miRNAs can have extremely far reaching effects and may affect the development of multiple diseases, including BC [4–8]. These results indicated that miRNAs may also be risk factors for BC.

miR-423 is located in frequently amplified region of chromosome 17q11.2 and can produce two mature
sequences: miR-423-3p and miR-423-5p [6]. Recent studies have shown that rs6505162: C > A, in pre-miR-423 increases risk of familial BC in families with a strong history of BC [7] and SNP rs6505162 in pre-miR-423 affects the mature miR expression, and then miR-423 may play a oncogenic role in breast tumorigenesis [8]. However, results of a recent meta-analysis including only two case-control studies on rs6505162 showed no relationship between rs6505162 polymorphism and BC risk [9]. Given the limited sample size, there is currently no consensus on whether there exists an association between rs6505162 polymorphism and BC risk.

As some new studies published, we conducted this meta-analysis of all relevant literatures to provide comprehensive and reliable insights. To the best of our knowledge, this is the first meta-analysis especially concerning rs6505162 polymorphism and BC risk, and it has the largest sample at present, compared with those published ones.

2. Materials and Methods

2.1. Search Strategy. All clinical and experimental case-control studies of polymorphisms in the miR-423 gene and BC published through May 15, 2021, were identified through systematic searches in PubMed, Embase, Google Scholar, and the Chinese National Knowledge Infrastructure (CNKI) databases, without language restrictions. The search terms used were: microRNA-423; miR-423; rs6505162; these three terms in combination with polymorphism, polymorphisms, SNP, variant, variants, variation, genotype, genetic, or mutation; and all of the above terms in combination with breast cancer, mammary cancer, or mammary adenocarcinoma. Reference lists in identified articles and reviews were also searched manually to identify additional eligible studies.

2.2. Inclusion Criteria. To be included in our review and meta-analysis, studies had to (1) have a case-control design for assessing the association between rs6505162 polymorphism and BC risk; (2) be accessible as a full-text article and report sufficient data for estimating odds ratios (ORs) with 95% confidence intervals (CIs); (3) report genotype frequencies; and (4) involve humans rather than animal models.

2.3. Data Extraction. Two authors (ZL and LJD) independently extracted the following data from included studies: first author’s family name, year of publication, ethnicity, testing methods, NOS score, P value for Hardy–Weinberg equilibrium (HWE) in controls, control source, sample size, matched parameters, and numbers and genotypes of cases and controls. Discrepancies were resolved by consensus. Only those studies that met the predetermined inclusion criteria were included.

2.4. Assessment of Methodological Quality. To assess the quality of the studies included in this analysis, the Newcastle–Ottawa Scale was applied independently by two assessors (ZL and LJD) [10] (Table 1). On the 10-point Newcastle–Ottawa Scale, scores of 5–9 points (stars) are considered to indicate generally high methodological quality, while scores of 0–4 stars are considered to indicate poor quality [11]. Any disagreements about Newcastle–Ottawa scores were resolved by other authors following a comprehensive reassessment. Only high-quality studies were included in the meta-analysis.

2.5. Statistical Analysis. Unadjusted odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association between rs6505162 polymorphism and BC risk based on genotype frequencies in cases and controls. The significance of pooled ORs was determined using the Z test, with P < 0.05 defined as the significance threshold. Meta-analysis was conducted using a fixed-effect model when P > 0.10 for the Q test, indicating lack of heterogeneity among studies; otherwise, a random-effect model was used. All these statistical tests were performed using Review Manager 5.3 (Cochrane Collaboration).

Publication bias was assessed using Begg’s funnel plots and Egger’s weighted regression in Stata 12.0 (Stata Corp., College Station, TX, USA), with P < 0.05 considered statistically significant.

3. Results

3.1. Description of Studies. Figure 1 shows a flowchart illustrating the process of searching for and selecting studies. A total of 294 potentially relevant publications were identified. Of these, we excluded 277 studies during initial screening based on review of the titles and abstracts. During analysis of the full text of the remaining articles, two studies were excluded for investigating other miRNAs [12, 13], two studies were excluded because they were review articles [14, 15], and one study was excluded because it did not report precise genotypes [16].

In the end, 12 studies [7, 17–27] were included in this meta-analysis based on our search strategy and inclusion criteria. Their characteristics and genotype distributions are summarized in Tables 1 and 2, respectively. The distribution of genotypes in controls was consistent with Hardy–Weinberg equilibrium (HWE, P > 0.05) in all but one study [25]. The overall quality of the included studies was adequate, and the mean Newcastle–Ottawa score for the included studies was 6.75 (Table 3).

3.2. Quantitative Data Synthesis. The meta-analysis of a possible association between rs6505162 polymorphism and BC risk is summarized in Table 4. Based on the total study population including 2,689 cases and 2,980 controls from 12 studies [7, 17–27], none of the five genetic models indicated a significant association: allelic model, OR 1.02, 95% CI 0.18–1.28, P = 0.85 (Figure 2(a)); recessive model, OR 0.99, 95% CI 0.72–1.38, P = 0.97 (Figure 2(b)); dominant model, OR 0.93, 95% CI 0.72–1.21, P = 0.60 (Figure 2(c)); homozygous model, OR 1.04, 95% CI 0.66–1.65, P = 0.87.
(Figure 2(d)); and heterozygous model, OR 1.07, 95% CI 0.90–1.28, P = 0.45 (Figure 2(e)).

Next we meta-analyzed data for subgroups based on ethnicity. Meta-analysis of 9 studies [19–27] involving 1,880 Asian cases and 1,793 Asian controls showed no evidence of a significant association rs6505162 polymorphism and BC risk in any of the five genetic models (Table 4): allelic model, OR = 1.09, 95% CI 0.82–1.44, P = 0.56; recessive model, OR = 1.10, 95% CI 0.75–1.61, P = 0.64; dominant model, OR = 0.81, 95% CI = 0.63–1.03, P = 0.09; homozygous model, OR = 1.20, 95% CI = 0.69–2.08, P = 0.52; and heterozygous model, OR = 1.20, 95% CI = 0.92–1.56, P = 0.18.

Similarly, no evidence of an association was identified in meta-analysis of 4 studies [19–22] involving 1,138 Chinese cases and 1,017 Chinese controls (Table 4): allelic model, OR = 1.12, 95% CI = 0.97–1.30, P = 0.13; recessive model, OR = 1.13, 95% CI = 0.95–1.35, P = 0.18; dominant model, OR = 0.81, 95% CI = 0.54–1.22, P = 0.32; homozygous model, OR = 1.29, 95% CI = 0.85–1.95, P = 0.24; and heterozygous model, OR = 1.15, 95% CI = 0.75–1.76, P = 0.53.

Also, no evidence of an association was identified in meta-analysis of 3 studies [7, 17, 18] involving 809 Caucasian cases and 1,187 Chinese controls (Table 4): allelic model, OR = 0.87, 95% CI = 0.58–1.31, P = 0.51; recessive model, OR = 0.75, 95% CI = 0.38–1.48, P = 0.41; dominant model, OR = 1.11, 95% CI = 0.74–1.66, P = 0.63; homozygous model, OR = 0.75, 95% CI = 0.33–1.70, P = 0.49; and

---

**Table 1: Characteristics of studies included in the meta-analysis.**

| First author          | Year | Ethnicity | Country   | Cancer type | Testing method | NOS score | P for HWE | Control source | Sample size (n) | Matched parameters                                                                 |
|-----------------------|------|-----------|-----------|-------------|----------------|-----------|-----------|----------------|----------------|-----------------------------------------------------------------------------------|
| Kontorovich et al.    | 2010 | Caucasian | Israel    | BRCA1,       | iPLEX         | 6         | 0.899     | PB             | 190 206         | Undetermined                                                                     |
| Smith et al.          | 2012 | Caucasian | Australia | —            | HRM            | 7         | 0.307     | HB             | 179 174         | Age, sex, ethnicity                                                              |
| Ma et al.             | 2013 | Asian     | China     | TNBC         | MassArray      | 7         | 0.847     | HB             | 192 189         | Age, sex, ethnicity, smoking status                                              |
| He et al.             | 2015 | Asian     | China     | —            | MassArray      | 8         | 0.103     | PB             | 450 450         | Age, menopausal status                                                           |
| Zhang et al.          | 2015 | Asian     | China     | —            | MassArray      | 8         | 0.847     | PB             | 382 189         | Age, smoking status                                                              |
| Zhao et al.           | 2015 | Asian     | China     | —            | Sequencing     | 6         | 0.847     | PB             | 114 189         | Undetermined                                                                     |
| Morales et al.        | 2016 | Caucasian | Chile     | —            | TaqMan         | 6         | 0.700     | HB             | 440 807         | Age, socioeconomic strata                                                       |
| Saedi et al.          | 2017 | Asian     | Iran      | —            | PCR-RFLP       | 6         | 0.196     | HB             | 353 353         | Undetermined                                                                     |
| Tran Thi et al.       | 2018 | Asian     | Vietnam   | —            | HRM            | 6         | 0.071     | PB             | 106 116         | Undetermined                                                                     |
| Mir et al.            | 2018 | Asian     | Saudi Arabia | —            | ARMS-PCR       | 7 <0.001  | PB          | 124 100        | Sex                                                                       |
| Mir et al.            | 2019 | Asian     | Saudi Arabia | —            | ARMS-PCR       | 7          | 0.152     | PB             | 30 30           | Sex                                                                       |
| Pourmoshir et al.     | 2020 | Asian     | Iran      | —            | ARMS-PCR       | 7          | 0.206     | PB             | 153 153         | Sex                                                                       |

Abbreviations: BRCA1, breast cancer type 1 susceptibility gene; BRCA2, breast cancer type 2 susceptibility gene; TNBC, triple-negative breast cancer; HB, hospital-based source of control; PB, population-based source of control; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; HRM, high-resolution melting; ARMS, amplification refractory mutation system; HWE, Hardy–Weinberg equilibrium.
| First author          | Year | Ethnicity | Country  | Sample size (cases/controls) | No. of cases | Allele frequencies of cases | No. of controls | Allele frequencies of controls |
|----------------------|------|-----------|----------|------------------------------|--------------|-----------------------------|----------------|------------------------------|
| Kontorovich et al. [17] | 2010 | Caucasian | Israel   | 190/206                      | 34 AA, 88 AC, 68 CC | 156 A, 224 C          | 49 AA, 102 AC, 55 CC | 200 A, 212 C          |
| Smith et al. [18]     | 2012 | Caucasian | Australia | 179/174                      | 60 AA, 95 AC, 24 CC | 215 A, 143 C          | 42 AA, 80 AC, 52 CC | 164 A, 184 C          |
| Ma et al. [19]        | 2013 | Asian     | China    | 192/189                      | 8 AA, 57 AC, 127 CC | 73 A, 311 C           | 10 AA, 69 AC, 110 CC | 89 A, 289 C           |
| He et al. [20]        | 2015 | Asian     | China    | 450/450                      | 16 AA, 142 AC, 292 CC | 174 A, 726 C          | 22 AA, 129 AC, 299 CC | 173 A, 727 C          |
| Zhang et al. [21]     | 2015 | Asian     | China    | 382/189                      | 20 AA, 131 AC, 231 CC | 171 A, 593 C          | 10 AA, 69 AC, 110 CC | 89 A, 289 C           |
| Zhao et al. [22]      | 2015 | Asian     | China    | 114/189                      | 5 AA, 30 AC, 79 CC  | 40 A, 188 C           | 10 AA, 69 AC, 110 CC | 89 A, 289 C           |
| Morales et al. [7]    | 2016 | Caucasian | Chile    | 440/807                      | 86 AA, 229 AC, 125 CC | 401 A, 479 C          | 138 AA, 385 AC, 284 CC | 661 A, 953 C          |
| Saedi et al. [23]     | 2017 | Asian     | Iran     | 353/353                      | 15 AA, 125 AC, 213 CC | 155 A, 551 C          | 36 AA, 137 AC, 180 CC | 209 A, 497 C          |
| Tran Thi et al. [24]  | 2018 | Asian     | Vietnam  | 106/116                      | 5 AA, 34 AC, 67 CC  | 44 A, 168 C           | 3 AA, 49 AC, 64 CC  | 55 A, 177 C           |
| Mir et al. [25]       | 2018 | Asian     | Saudi Arabia | 100/124                    | 23 AA, 52 AC, 25 CC | 98 A, 102 C          | 18 AA, 25 AC, 81 CC | 61 A, 187 C          |
| Mir et al. [26]       | 2019 | Asian     | Saudi Arabia | 30/30                       | 3 AA, 11 AC, 16 CC  | 17 A, 43 C           | 4 AA, 9 AC, 17 CC  | 17 A, 43 C           |
| Pourmoshir et al. [27] | 2020 | Asian     | Iran     | 153/153                      | 59 AA, 46 AC, 48 CC | 164 A, 142 C          | 67 AA, 63 AC, 23 CC | 197 A, 109 C          |

Abbreviations: mir-423, microRNA-423.
| Study                  | Adequate definition of patient cases | Representativeness of patient cases | Selection of controls | Definition of controls | Control for important factor or additional factor | Ascertainment of exposure (blinding) | Same method of ascertainment for participants | Non-response rate<sup>a</sup> | Total score<sup>b</sup> |
|-----------------------|-------------------------------------|------------------------------------|-----------------------|------------------------|----------------------------------|-----------------------------------|---------------------------------------------|-------------------------------|---------------------|
| Kontorovich et al. [17] | 1                                  | 1                                  | 1                     | 1                      | 0                                | 0                                 | 1                            | 1                             | 6                   |
| Smith et al. [18]     | 1                                  | 1                                  | 0                     | 1                      | 2                                | 0                                 | 1                            | 1                             | 7                   |
| Ma et al. [19]        | 1                                  | 1                                  | 0                     | 1                      | 2                                | 0                                 | 1                            | 1                             | 7                   |
| He et al. [20]        | 1                                  | 1                                  | 1                     | 1                      | 2                                | 0                                 | 1                            | 1                             | 8                   |
| Zhang et al. [21]     | 1                                  | 1                                  | 1                     | 1                      | 2                                | 0                                 | 1                            | 1                             | 8                   |
| Zhao et al. [22]      | 1                                  | 1                                  | 1                     | 1                      | 0                                | 0                                 | 1                            | 1                             | 6                   |
| Morales et al. [7]    | 1                                  | 1                                  | 0                     | 1                      | 1                                | 0                                 | 1                            | 1                             | 6                   |
| Saedi et al. [23]     | 1                                  | 1                                  | 0                     | 1                      | 1                                | 0                                 | 1                            | 1                             | 6                   |
| Tran Thi et al. [24]  | 1                                  | 1                                  | 1                     | 1                      | 0                                | 0                                 | 1                            | 1                             | 6                   |
| Mir et al. [25]       | 1                                  | 1                                  | 1                     | 1                      | 1                                | 0                                 | 1                            | 1                             | 7                   |
| Mir et al. [26]       | 1                                  | 1                                  | 1                     | 1                      | 1                                | 0                                 | 1                            | 1                             | 7                   |
| Pourmoshir et al. [27] | 1                                | 1                                  | 1                     | 1                      | 1                                | 0                                 | 1                            | 1                             | 7                   |

<sup>a</sup>When there was no significant difference in the response rate between both groups based on a chi-squared test ($P > 0.05$), one point was awarded. <sup>b</sup>Total score was calculated by adding up the points awarded in each item.
| Study or subgroup | Cases | Controls | Weight | Odds Ratio [95% CI] | Heterogeneity: \( I^2 \) (%) |
|------------------|-------|----------|--------|---------------------|-----------------------------|
| **Total**        | 1573  | 1549     | 1.82   | 0.89 [0.32, 2.42]   | 53.2                         |
| Total events     | 1055  | 1055     | 1.82   | 0.89 [0.32, 2.42]   | 53.2                         |

**Abbreviations:** miR-423, microRNA-423; OR, odds ratios; 95% CI, 95% confidence interval.

**Figure 2:** Continued.
heterozygous model, OR = 0.98, 95% CI = 0.77–1.24, P = 0.84.

Lastly, no evidence of an association was identified in meta-analysis of 5 studies [18–21, 27] involving 1,356 female cases and 1,155 female controls (Table 4): allelic model, OR = 1.05, 95% CI = 0.77–1.42, P = 0.78; recessive model, OR = 1.06, 95% CI = 0.66–1.71, P = 0.81; dominant model, OR = 1.00, 95% CI = 0.77–1.30, P = 0.99; homozygous model, OR = 1.08, 95% CI = 0.52–2.27, P = 0.83; and heterozygous model, OR = 0.95, 95% CI = 0.72–1.26, P = 0.73.

3.3. Sensitivity Analysis. The robustness of the meta-analysis of 12 studies examining a possible association between rs6505162 polymorphism and BC risk was assessed by repeating the meta-analysis after excluding a study [25] in which the P value associated with HWE was less than 0.05. Deleting these data from the meta-analysis did not alter the results obtained using any of the five genetic models, whether for the entire study population or the Asian population.

3.4. Publication Bias. Potential publication bias in this meta-analysis was assessed using Begg’s funnel plot and Egger’s test. In any of the five genetic models, respectively, no obvious asymmetry was observed in Begg’s funnel plots (Figures 3(a), 3(c), 3(e), 3(g), and 3(i)) and Egger’s test of rs6505162 polymorphism (Figures 3(b), 3(d), 3(f), 3(h), and 3(j)). P values for Begg’s funnel plots and Egger’s tests were all greater than 0.05. These results suggest no potential publication bias.

4. Discussion

In order to investigate the relationship between rs6505162 polymorphism and BC risk, a few recent meta-analyses [9, 28–30] have reported their findings. However, their results were inconsistent. Meta-analysis by Chen et al. [28] with 16 case-control studies included suggested that rs6505162 polymorphism might be associated with a reduced risk of cancers but not with BC risk in subgroup analysis of 5 case-control studies. Meta-analysis by Zhang et al. [29] with 6 case-control studies included suggested that a significantly decreased cancer risk was observed in lung cancer for rs6505162 but not in BC risk. Meta-analysis by Li et al. [30] with 8 case-control studies included suggested rs6505162 decreases the risk of cancer, showing that it is the protective factor of cancer. But subgroup analysis for BC risk was not performed.

Those previous meta-analyses did not specially focus on BC, much less on BC by subgroup analysis by ethnicity. In order to evaluate available evidence on the possible association between rs6505162 polymorphism in miR-423 promoter and BC risk, a more detailed meta-analysis was performed. Results showed that miR-423 rs6505162 might not be associated with BC risk, regardless of ethnicity. Even though our results supported previous studies [28, 29], given larger sample with 12 case-control studies included, ours should be more convincing.

Although null results were obtained in the current study on rs6505162 polymorphism with larger sample, we really hope they would provide a reference for future studies. Nonetheless, the work still has several limitations that may affect interpretation of the results. Firstly, the P value for HWE in one study [25] was less than 0.05, making these study populations not being representative of the broader target population. Nevertheless, sensitivity analyses showed that deleting the study did not alter the results. Secondly, the studies may be subject to performance bias, attrition bias, and reporting bias, although Newcastle–Ottawa scores were more than 5 for all studies, indicating high quality. Thirdly, additional confounding factors such as age, gender, and tumor status may affect the results. In order to reduce the effect of those confounding factors above on the results, we have tried our best to make stratified analysis based on those factors. In the end, only gender could be taken into account. A total of 5 case-control studies [18–21, 27] of which the patients were all definitely female were selected to investigate the relationship between rs6505162 polymorphism and BC risk on females. Nevertheless, these studies either did not report age and tumor status or aggregated them in different ways, resulting in a failure to include them in the meta-analysis. Lastly, methods used to test for polymorphisms were not uniform and they varied in sensitivity and specificity, which may reduce the robustness of the meta-analysis.
Figure 3: Continued.
In conclusion, this study performed an extensive assessment based on a larger sample size than the previous pooled analysis and suggested no significant association between miR-423 rs6505162 polymorphism and BC risk. These conclusions should be verified in large, well-designed studies.

**Abbreviations**

miR: MicroRNA  
BC: Breast cancer  
HWE: Hardy–Weinberg equilibrium  
CNKI: Chinese National Knowledge Infrastructure  
OR: Odds ratios  
95% CI: 95% confidence interval  
TNBC: Triple-negative breast cancer  
HB: Hospital-based source of control  
PB: Population-based source of control  
PCR: Polymerase chain reaction  
RFLP: Restriction fragment length polymorphism  
HRM: High-resolution melting  
ARMS: Amplification refractory mutation system.

**Data Availability**

The data used to support the findings of this study are included within the article.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] M. F. Ullah, “Breast cancer: current perspectives on the disease status,” *Advances in Experimental Medicine and Biology*, vol. 1152, pp. 51–64, 2019.
[2] K. McPherson, “Breast cancer—epidemiology, risk factors, and genetics,” *BMJ British Medical Journal*, vol. 309, no. 7261, pp. 1003–1006, 1994.
[3] F. Qian, Y. Feng, Y. Zheng et al., “Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry,” *Human Genetics*, vol. 135, no. 10, pp. 1145–1159, 2016.
[4] S. Morales, T. De Mayo, F. Gulppi et al., “Genetic variants in pre-miR-146a, pre-miR-499, pre-miR-125a, pre-miR-605, and pri-miR-182 are associated with breast cancer.
susceptibility in a south American population,” Genes, vol. 9, no. 9, p. 427, 2018.

[5] M. R. Ladomery, D. G. Maddocks, and I. D. Wilson, “MicroRNAs: their discovery, biogenesis, function and potential use as biomarkers in non-invasive prenatal diagnostics,” International Journal of Molecular Epidemiology and Genetics, vol. 2, no. 3, pp. 253–260, 2011.

[6] J. Lin, S. Huang, S. Wu et al., “MicroRNA-423 promotes cell growth and regulates G 1/S transition by targeting p21Cip1/ Waf1 in hepatocellular carcinoma,” Carcinogenesis, vol. 32, no. 11, pp. 1641–1647, 2011.

[7] S. Morales, F. Gulppi, P. Gonzalez-Hormazabal et al., “Association of single nucleotide polymorphisms in Pre-miR-27a, Pre-miR-196a2, Pre-miR-423, miR-608 and Pre-miR-618 with breast cancer susceptibility in a south American population,” BMC Genetics, vol. 17, p. 109, 2016.

[8] H. Zhao, A. Gao, Z. Zhang et al., “Genetic analysis and preliminary function study of miR-423 in breast cancer,” Tumor Biology, vol. 36, no. 6, pp. 4763–4771, 2015.

[9] Q.-H. Chen, Q.-B. Wang, and B. Zhang, “Ethnicity modifies the association between functional microRNA polymorphisms and breast cancer risk: a HuGE meta-analysis,” Tumor Biology, vol. 35, no. 1, pp. 529–543, 2014.

[10] G. A. Wells, B. Shea, D. O’Connell et al., “The newcastle-ottawa scale (NOS) for assessing the quality of non-randomised studies in meta-analyses,” 2000, http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.

[11] R. L. Ownby, E. Crocco, A. Acevedo, V. John, and D. Loewenstein, “Depression and risk for alzheimer disease,” Archives of General Psychiatry, vol. 63, no. 5, pp. 530–538, 2006.

[12] Z. Hu, J. Liang, Z. Wang et al., “Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women,” Human Mutation, vol. 30, no. 1, pp. 79–84, 2009.

[13] K. M. T. Arif, G. Bradshaw, T. T. N. Nguyen et al., “Genetic association analysis implicates six MicroRNA-related SNPs with increased risk of breast cancer in Australian caucasion women,” Clinical Breast Cancer, vol. S1526-8209, no. 21, 2021.

[14] F. Bahreini, E. Rayzan, and N. Rezaei, “microRNA-related single-nucleotide polymorphisms and breast cancer,” Journal of Cellular Physiology, vol. 236, no. 3, pp. 1593–1605, 2021.

[15] G. Farnoosh, A. Saeedi-Boroujeni, A. Jalali, B. Keikhaei, and M.-R. Mahmoudian-Sani, “Polymorphisms in genes involved in breast cancer among Iranian patients,” Personalized Medicine, vol. 18, no. 2, pp. 153–169, 2021.

[16] C. B. Zhu, Y. Q. Pan, and B. S. He, “Study on the association of polymorphisms in microRNAs and risk of breast cancer and its clinic pathological parameters,” Medical Journal of Southeast China, vol. 17, no. 1, pp. 22–25, 2015.

[17] T. Kontorovich, A. Levy, M. Korostishevsky, U. Nir, and E. Friedman, “Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women,” International Journal of Cancer, vol. 127, no. 3, pp. 589–597, 2010.

[18] R. A. Smith, D. J. Jedlinski, P. N. Gabrovskva, S. R Weinstein, L Haupt, and L. R Griffihls, “A genetic variant located in miR-423 is associated with reduced breast cancer risk,” Cancer Genomics and Proteomics, vol. 9, no. 3, pp. 115–118, 2012.

[19] F. Ma, P. Zhang, D. Lin et al., “There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population,” PLoS One, vol. 8, no. 3, Article ID e60195, 2013.